600721-43-5

Basic information

• Product Name: 1H-Isoindole-1,3(2H)-dione, 2-[2,6-dioxo-1-(phenylmethoxy)-3-piperidinyl]-
• CAS NO: 600721-43-5
• Molecular Formula: C20H16N2O5
• Molecular Weight: 364.357
• Mol File: 600721-43-5.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 1H-Isoindole-1,3(2H)-dione, 2-[2,6-dioxo-1-(phenylmethoxy)-3-piperidinyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-Isoindole-1,3(2H)-dione, 2-[2,6-dioxo-1-(phenylmethoxy)-3-piperidinyl]-(600721-43-5)
• EPA Substance Registry System: 1H-Isoindole-1,3(2H)-dione, 2-[2,6-dioxo-1-(phenylmethoxy)-3-piperidinyl]-(600721-43-5)

Safety Data

• Hazardous Substances Data: 600721-43-5(Hazardous Substances Data)

Upstream product

• 622-33-3 N-benzyloxyamine 
• 3343-28-0 N-phthaloylglutamic acid anhydride 
• 6349-98-0 N-phthalylglutamic acid 
• 2687-43-6 O-benzylhydoxylamine hydrochloride 

Downstream Products

• 600721-44-6 1-benzyloxy-3-(1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione 
• 26581-81-7 3-(1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione 
• 126663-38-5 N-Hydroxythalidomide 

Relevant articles and documents

Mono- and dihydroxylated metabolites of thalidomide: Synthesis and TNF-α production-inhibitory activity

Mono- and dihydroxylated metabolites of thalidomide were efficiently prepared and characterized, and their inhibitory activity on tumor necrosis factor (TNF)-α production in the human monocytic leukemia cell line THP-1 was evaluated. 5,N-Dihydroxythalidomide was a much more potent TNF-α production inhibitor than thalidomide.

Thalidomide metabolites and analogues. 3. Synthesis and antiangiogenic activity of the teratogenic and TNFα-modulatory thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine

Versatile synthesis of the teratogenic, TNFα-modulatory, and antiangiogenic thalidomide analogue 2-(2,6-dioxopiperidine-3-yl)phthalimidine (1) and its direct antiangiogenic properties are described. With thalidomide or thalidomide derivatives as precursors, the synthesis involved either carbonyl reduction/thiation-desulfurization or carbonyl reduction/acyliminium ion reduction protocols. Compared to earlier studies with thalidomide, which was only active with microsomal treatment, 1 exhibited marginal inhibitory activity in the rat aortic ring assay, thereby demonstrating the requirement for metabolic activation.